Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
It is usually brown or black but can also be skin-colored, purple, blue, red, pink, or white
The challenge on GLP-1 medications is getting enough fiber from food when your total caloric intake has dropped significantly
Ipamorelin peptide therapy is typically administered through subcutaneous injections
The subcutaneous tissue in the upper arm is thinner than the abdomen or thigh for most individuals, so a 45-degree angle with a shorter needle often works better here
Results accelerate in months 23 as your body adapts and you settle into consistent eating patterns
